Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Novo Nordisk Is Now Europe's Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.
05:06am, Tuesday, 05'th Sep 2023
The pharma company's Wegovy medication helps it overtake luxury goods maker LVMH, with a market value of around $420 billion.
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
07:01am, Friday, 01'st Sep 2023
Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen In
Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)
04:31am, Thursday, 31'st Aug 2023
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
7 Stocks Sitting At 52-Week Highs Right Now
07:17pm, Wednesday, 30'th Aug 2023
Propelled by strong earnings and upbeat guidance, the shares of several leading companies are now at their highest level in a year. And while some investors might be weary of stocks trading at 52-week
3 Dividend Stocks That Have Doubled Since 2020
01:48pm, Wednesday, 30'th Aug 2023
Bullishness in AI and weight-loss treatments have made Nvidia and Eli Lilly hot investments to own this year. Dick's Sporting Goods crashed in August after the company cut its guidance, but its gains
3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of
08:54am, Wednesday, 30'th Aug 2023
This year has not been kind to biotech stocks, as the sector's most popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB ), has fallen about 3% so far in 2023. Investors are probably worried about
The 3 Most Promising Pharma Stocks to Own Now
05:20am, Wednesday, 30'th Aug 2023
It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of severe dise
Global dividends hit record $568 billion, but pace of U.S. payouts slows for sixth straight quarter
01:57am, Wednesday, 30'th Aug 2023
Global dividends rose 4.9% to a record $568 billion in the second quarter, but the pace of growth in the U.S. slowed for the sixth consecutive quarter after some high- profile technology and financial
What the medicare decision means for pharma stocks
06:37pm, Tuesday, 29'th Aug 2023
Jared Holz, Mizuho, joins 'Fast Money' to talk the Biden Administration unveiling the first 10 drugs subject to medicare price negotiations and how pharma stocks are responding.
Better Pharma Growth Stock: Eli Lilly vs. Merck
10:15am, Tuesday, 29'th Aug 2023
Eli Lilly's Mounjaro is shaping up to be a long-term driver of earnings growth. The same is true for Merck's Keytruda, a medication for treating certain cancers.
Better Buy: Biogen vs. Eli Lilly
10:07am, Tuesday, 29'th Aug 2023
Biogen is adding new products to its lineup to reverse its recent revenue decreases. Eli Lilly has a solid portfolio and strong pipeline, and pays a consistent dividend.
Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference
10:00am, Tuesday, 29'th Aug 2023
INDIANAPOLIS , Aug. 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 21st Annual Global Healthcare Conference, Sept. 11-12, 2023.
Why Wegovy's Sales Potential Could Be Massively Understated
05:47am, Tuesday, 29'th Aug 2023
Wegovy may generate more than $4 billion in revenue this year for Novo Nordisk. A recent study showed the weight-loss drug can also help people bring down their risk of heart attack or stroke.
Eli Lilly's diabetes drug to remain in shortage in EU through September
10:58am, Monday, 28'th Aug 2023
The European Medicines Agency (EMA) said on Monday Eli Lilly & Co's Trulicity, which treats type 2 diabetes in children above 10 years of age, will continue to remain in shortage in Europe through Sep
The 3 Blue-Chip Stocks Every Investor Needs to Own Today
08:10am, Monday, 28'th Aug 2023
Savvy investors understand the beauty of having blue-chip stocks. No wonder financial analysts and market professionals recommend having them in your portfolio.
